Weight gain and antipsychotics: a drug safety review

Bibliography

• Baptista T, ElFakih Y, Uzcategui E, et al. Pharmacological management of atypical antipsychotic-induced weight gain. CNS Drugs 2008;22(6):477-95
   PubMed Web of Science ®Google Scholar
• McKean A, Monasterio E. Off-label use of atypical antipsychotics: cause for concern? CNS Drugs 2012;26(5):383-90
   PubMed Web of Science ®Google Scholar
• Pfeifer JC, Kowatch RA, DelBello MP. Pharmacotherapy of bipolar disorder in children and adolescents: recent progress. CNS Drugs 2010;24(7):575-93
   PubMed Web of Science ®Google Scholar
• Wong MM, Chen EY, Lui SS, Tso S. Medication adherence and subjective weight perception in patients with first-episode psychotic disorder. Clin Schizophr Relat Psychoses 2011;5(3):135-41
   PubMedGoogle Scholar
• Yan H, Chen JD, Zheng XY. Potential mechanisms of atypical antipsychotic-induced hypertriglyceridemia. Psychopharmacology (Berl) 2013;229(1):1-7
   PubMed Web of Science ®Google Scholar
• De Hert M, Detraux J, van Winkel R, et al. Metabolic and cardiovascular adverse effects associated with antipsychotic drugs. Nat Rev Endocrinol 2012;8(2):114-26
   Web of Science ®Google Scholar
• Correll CU, Kane JM, Manu P. Obesity and coronary risk in patients treated with second-generation antipsychotics. Eur Arch Psychiatry Clin Neurosci 2011;261(6):417-23
   PubMed Web of Science ®Google Scholar
• Kao AC, Muller DJ. Genetics of antipsychotic-induced weight gain: update and current perspectives. Pharmacogenomics 2013;14(16):2067-83
   PubMed Web of Science ®Google Scholar
• Milano W, De Rosa M, Milano L, Capasso A. Antipsychotic drugs opposite to metabolic risk: neurotransmitters, neurohormonal and pharmacogenetic mechanisms underlying with weight gain and metabolic syndrome. Open Neurol J 2013;7:23-31
   PubMedGoogle Scholar
• Roerig JL, Steffen KJ, Mitchell JE. Atypical antipsychotic-induced weight gain: insights into mechanisms of action. CNS Drugs 2011;25(12):1035-59
   PubMed Web of Science ®Google Scholar
• Lasser RA, Mao L, Gharabawi G. Smokers and nonsmokers equally affected by olanzapine-induced weight gain: metabolic implications. Schizophr Res 2004;66(2-3):163-7
   PubMed Web of Science ®Google Scholar
• Allison DB, Mentore JL, Heo M, et al. Antipsychotic-induced weight gain: a comprehensive research synthesis. Am J Psychiatry 1999;156(11):1686-96
   PubMed Web of Science ®Google Scholar
• Lieberman JA, Stroup TS, McEvoy JP, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005;353(12):1209-23
   PubMed Web of Science ®Google Scholar
• Hasnain M, Vieweg WV, Hollett B. Weight gain and glucose dysregulation with second-generation antipsychotics and antidepressants: a review for primary care physicians. Postgrad Med 2012;124(4):154-67
   PubMed Web of Science ®Google Scholar
• Leucht S, Cipriani A, Spineli L, et al. Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. Lancet 2013;382(9896):951-62
   PubMed Web of Science ®Google Scholar
• Bowden CL. Atypical antipsychotic augmentation of mood stabilizer therapy in bipolar disorder. J Clin Psychiatry 2005;66(Suppl 3):12-19
   PubMedGoogle Scholar
• DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986;7(3):177-88
   PubMedGoogle Scholar
• R DCT. R: A language and environment for statistical computing. "meta". 3.7-1 ed R Foundation for Statistical Computing; Vienna, Austria: 2008
   Google Scholar
• Correll CU. Safety and tolerability of antipsychotic treatment in young patients with schizophrenia. J Clin Psychiatry 2011;72(8):e26
   PubMedGoogle Scholar
• Martinez-Ortega JM, Funes-Godoy S, Diaz-Atienza F, et al. Weight gain and increase of body mass index among children and adolescents treated with antipsychotics: a critical review. Eur Child Adolesc Psychiatry 2013;22(8):457-79
   PubMed Web of Science ®Google Scholar
• Moreno C, Merchan-Naranjo J, Alvarez M, et al. Metabolic effects of second-generation antipsychotics in bipolar youth: comparison with other psychotic and nonpsychotic diagnoses. Bipolar Disord 2010;12(2):172-84
   PubMed Web of Science ®Google Scholar
• Kryzhanovskaya LA, Xu W, Millen BA, et al. Comparison of long-term (at least 24 weeks) weight gain and metabolic changes between adolescents and adults treated with olanzapine. J Child Adolesc Psychopharmacol 2012;22(2):157-65
   PubMed Web of Science ®Google Scholar
• Greil W, Haberle A, Schuhmann T, et al. Age and adverse drug reactions from psychopharmacological treatment: data from the AMSP drug surveillance programme in Switzerland. Swiss Med Wkly 2013;143:w13772
   PubMed Web of Science ®Google Scholar
• Greil W, Haberle A, Schuhmann T, et al. Age and adverse drug reactions from psychopharmacological treatment. Swiss Med Wkly 2013;143
   PubMed Web of Science ®Google Scholar
• De Hert M, Dobbelaere M, Sheridan EM, et al. Metabolic and endocrine adverse effects of second-generation antipsychotics in children and adolescents: a systematic review of randomized, placebo controlled trials and guidelines for clinical practice. Eur Psychiatry 2011;26(3):144-58
   PubMed Web of Science ®Google Scholar
• Fraguas D, Correll CU, Merchan-Naranjo J, et al. Efficacy and safety of second-generation antipsychotics in children and adolescents with psychotic and bipolar spectrum disorders: comprehensive review of prospective head-to-head and placebo-controlled comparisons. Eur Neuropsychopharmacol 2011;21(8):621-45
   PubMed Web of Science ®Google Scholar
• Tarricone I, Gozzi BF, Serretti A, et al. Weight gain in antipsychotic-naive patients: a review and meta-analysis. Psychol Med 2010;40(2):187-200
   PubMed Web of Science ®Google Scholar
• Roy G, Bedard A, Desmarais PA, et al. Age-dependent metabolic effects of second-generation antipsychotics in second-generation antipsychotic-naive French Canadian patients. J Child Adolesc Psychopharmacol 2010;20(6):479-87
   PubMed Web of Science ®Google Scholar
• Bushe CJ, Slooff CJ, Haddad PM, Karagianis JL. Weight change by baseline BMI from three-year observational data: findings from the Worldwide Schizophrenia Outpatient Health Outcomes Database. J Psychopharmacol 2013;27(4):358-65
   PubMed Web of Science ®Google Scholar
• Lee SY, Park MH, Patkar AA, Pae CU. A retrospective comparison of BMI changes and the potential risk factors among schizophrenic inpatients treated with aripiprazole, olanzapine, quetiapine or risperidone. Prog Neuropsychopharmacol Biol Psychiatry 2011;35(2):490-6
   PubMed Web of Science ®Google Scholar
• Aichhorn W, Whitworth AB, Weiss EM, Marksteiner J. Second-generation antipsychotics: is there evidence for sex differences in pharmacokinetic and adverse effect profiles? Drug Saf 2006;29(7):587-98
   PubMed Web of Science ®Google Scholar
• Perez-Iglesias R, Martinez-Garcia O, Pardo-Garcia G, et al. Course of weight gain and metabolic abnormalities in first treated episode of psychosis: the first year is a critical period for development of cardiovascular risk factors. Int J Neuropsychopharmacol 2014;17(1):41-51
   PubMed Web of Science ®Google Scholar
• Davey KJ, O’Mahony SM, Schellekens H, et al. Gender-dependent consequences of chronic olanzapine in the rat: effects on body weight, inflammatory, metabolic and microbiota parameters. Psychopharmacology (Berl) 2012;221(1):155-69
   PubMed Web of Science ®Google Scholar
• Seeman MV. Schizophrenia: women bear a disproportionate toll of antipsychotic side effects. J Am Psychiatr Nurses Assoc 2010;16(1):21-9
   PubMedGoogle Scholar
• Cutler AJ, Kalali AH, Mattingly GW, et al. Long-term safety and tolerability of iloperidone: results from a 25-week, open-label extension trial. CNS Spectr 2013;18(1):43-54
   PubMed Web of Science ®Google Scholar
• Jerrell JM. Adverse events associated with psychotropic treatment in African American children and adolescents. J Natl Med Assoc 2010;102(5):375-83
   PubMed Web of Science ®Google Scholar
• Bou Khalil R. Atypical antipsychotic drugs, schizophrenia, and metabolic syndrome in non-Euro-American societies. Clin Neuropharmacol 2012;35(3):141-7
   PubMed Web of Science ®Google Scholar
• Komossa K, Rummel-Kluge C, Hunger H, et al. Amisulpride versus other atypical antipsychotics for schizophrenia. Cochrane Database Syst Rev 2010(1):CD006624
   PubMed Web of Science ®Google Scholar
• Bushe CJ, Slooff CJ, Haddad PM, Karagianis JL. Weight change from 3-year observational data: findings from the worldwide schizophrenia outpatient health outcomes database. J Clin Psychiatry 2012;73(6):e749-55
   PubMedGoogle Scholar
• Kahn RS, Fleischhacker WW, Boter H, et al. Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial. Lancet 2008;371(9618):1085-97
   PubMed Web of Science ®Google Scholar
• Ceskova E, Suchopar J, Priborska Z. Safety of amisulpride in combination with antidepressants under common clinical practice conditions. Int J Psychiatry Clin Pract 2011;15(2):157-61
   PubMed Web of Science ®Google Scholar
• Khanna P, Komossa K, Rummel-Kluge C, et al. Aripiprazole versus other atypical antipsychotics for schizophrenia. Cochrane Database Syst Rev 2013;2:CD006569
   PubMedGoogle Scholar
• Khanna P, Suo T, Komossa K, et al. Aripiprazole versus other atypical antipsychotics for schizophrenia. Cochrane Database Syst Rev 2014;1:CD006569.
   Google Scholar
• Kane JM, Sanchez R, Perry PP, et al. Aripiprazole intramuscular depot as maintenance treatment in patients with schizophrenia: a 52-week, multicenter, randomized, double-blind, placebo-controlled study. J Clin Psychiatry 2012;73(5):617-24
   PubMed Web of Science ®Google Scholar
• Citrome L, Kalsekar I, Baker RA, Hebden T. A review of real-world data on the effects of aripiprazole on weight and metabolic outcomes in adults. Curr Med Res Opin 2014;30(8):1629-41
   PubMed Web of Science ®Google Scholar
• Ching H, Pringsheim T. Aripiprazole for autism spectrum disorders (ASD). Cochrane Database Syst Rev 2012;5:CD009043
   PubMed Web of Science ®Google Scholar
• Cohen D, Raffin M, Canitano R, et al. Risperidone or aripiprazole in children and adolescents with autism and/or intellectual disability: a Bayesian meta-analysis of efficacy and secondary effects. Res Autism Spect Dis 2013;7(1):167-75
   Web of Science ®Google Scholar
• Carlson BX, Ketter TA, Sun W, et al. Aripiprazole in combination with lamotrigine for the long-term treatment of patients with bipolar I disorder (manic or mixed): a randomized, multicenter, double-blind study (CN138-392). Bipolar Disord 2012;14(1):41-53
   PubMed Web of Science ®Google Scholar
• Komossa K, Depping AM, Gaudchau A, et al. Second-generation antipsychotics for major depressive disorder and dysthymia. Cochrane Database Syst Rev 2010(12):CD008121
   Google Scholar
• Spielmans GI, Berman MI, Linardatos E, et al. Adjunctive atypical antipsychotic treatment for major depressive disorder: a meta-analysis of depression, quality of life, and safety outcomes. PLoS Med 2013;10(3):e1001403
   PubMed Web of Science ®Google Scholar
• Gao K, Kemp DE, Fein E, et al. Number needed to treat to harm for discontinuation due to adverse events in the treatment of bipolar depression, major depressive disorder, and generalized anxiety disorder with atypical antipsychotics. J Clin Psychiatry 2011;72(8):1063-71
   PubMed Web of Science ®Google Scholar
• Fleischhacker WW, Heikkinen ME, Olie JP, et al. Effects of adjunctive treatment with aripiprazole on body weight and clinical efficacy in schizophrenia patients treated with clozapine: a randomized, double-blind, placebo-controlled trial. Int J Neuropsychopharmacol 2010;13(8):1115-25
   PubMed Web of Science ®Google Scholar
• Stroup TS, McEvoy JP, Ring KD, et al. A Randomized Trial Examining the Effectiveness of Switching From Olanzapine, Quetiapine, or Risperidone to Aripiprazole to Reduce Metabolic Risk: comparison of Antipsychotics for Metabolic Problems (CAMP). Am J Psychiatry 2011;168(9):947-56
   PubMed Web of Science ®Google Scholar
• Barak Y, Aizenberg D. Switching to aripiprazole as a strategy for weight reduction: a meta-analysis in patients suffering from schizophrenia. J Obes 2011;2011
   PubMedGoogle Scholar
• De Hert M, Detraux J, van Winkel R, et al. Metabolic and cardiovascular adverse effects associated with antipsychotic drugs. Nat Rev Endocrinol 2012;8(2):114-26
   Web of Science ®Google Scholar
• De Hert M, Yu W, Detraux J, et al. Body weight and metabolic adverse effects of asenapine, iloperidone, lurasidone and paliperidone in the treatment of schizophrenia and bipolar disorder: a systematic review and exploratory meta-analysis. CNS Drugs 2012;26(9):733-59
   PubMed Web of Science ®Google Scholar
• Citrome L. Asenapine for schizophrenia and bipolar disorder: a review of the efficacy and safety profile for this newly approved sublingually absorbed second-generation antipsychotic. Int J Clin Pract 2009;63(12):1762-84
   PubMed Web of Science ®Google Scholar
• Kemp DE, Zhao J, Cazorla P, et al. Weight change and metabolic effects of asenapine in patients with schizophrenia and bipolar disorder. J Clin Psychiatry 2013;75(3):238-45
   Web of Science ®Google Scholar
• McIntyre RS, Cohen M, Zhao J, et al. Asenapine for long-term treatment of bipolar disorder: a double-blind 40-week extension study. J Affect Disord 2010;126(3):358-65
   PubMed Web of Science ®Google Scholar
• Dubovsky SL, Frobose C, Phiri P, et al. Short-term safety and pharmacokinetic profile of asenapine in older patients with psychosis. Int J Geriatr Psychiatry 2012;27(5):472-82
   PubMed Web of Science ®Google Scholar
• Geoffroy PA, Etain B, Henry C, Bellivier F. Combination therapy for manic phases: a critical review of a common practice. CNS Neurosci Ther 2012;18(12):957-64
   PubMed Web of Science ®Google Scholar
• Rummel-Kluge C, Komossa K, Schwarz S, et al. Head-to-head comparisons of metabolic side effects of second generation antipsychotics in the treatment of schizophrenia: a systematic review and meta-analysis. Schizophr Res 2010;123(2-3):225-33
   PubMed Web of Science ®Google Scholar
• Asenjo Lobos C, Komossa K, Rummel-Kluge C, et al. Clozapine versus other atypical antipsychotics for schizophrenia. Cochrane Database Syst Rev 2010(11):CD006633
   PubMed Web of Science ®Google Scholar
• Schneider C, Corrigall R, Hayes D, et al. Systematic review of the efficacy and tolerability of Clozapine in the treatment of youth with early onset schizophrenia. Eur Psychiatry 2014;29(1):1-10
   PubMed Web of Science ®Google Scholar
• Beduin AS, de Haan L. Off-Label Second Generation Antipsychotics for Impulse Regulation Disorders: a Review. Psychopharmacol Bull 2010;43(3):45-81
   Web of Science ®Google Scholar
• Meltzer HY, Bobo WV, Lee MA, et al. A randomized trial comparing clozapine and typical neuroleptic drugs in non-treatment-resistant schizophrenia. Psychiatry Res 2010;177(3):286-93
   PubMed Web of Science ®Google Scholar
• Zipursky RB, Gu H, Green AI, et al. Course and predictors of weight gain in people with first-episode psychosis treated with olanzapine or haloperidol. Br J Psychiatry 2005;187:537-43
   PubMed Web of Science ®Google Scholar
• Peluso MJ, Lewis SW, Barnes TRE, Jones PB. Non-neurological and metabolic side effects in the Cost Utility of the Latest Antipsychotics in Schizophrenia Randomised Controlled Trial (CUtLASS-1). Schizophr Res 2013;144(1-3):80-6
   PubMed Web of Science ®Google Scholar
• Weiden PJ, Citrome L, Alva G, et al. A trial evaluating gradual- or immediate-switch strategies from risperidone, olanzapine, or aripiprazole to iloperidone in patients with schizophrenia. Schizophr Res 2014;153(1-3):160-8
   PubMed Web of Science ®Google Scholar
• Citrome L. Lurasidone for the acute treatment of adults with schizophrenia: what is the number needed to treat, number needed to harm, and likelihood to be helped or harmed? Clin Schizophr Relat Psychoses 2012;6(2):76-85
   PubMedGoogle Scholar
• Citrome L, Weiden PJ, McEvoy JP, et al. Effectiveness of lurasidone in schizophrenia or schizoaffective patients switched from other antipsychotics: a 6-month, open-label, extension study. CNS Spectr 2013;1-10
   PubMedGoogle Scholar
• Komossa K, Rummel-Kluge C, Hunger H, et al. Olanzapine versus other atypical antipsychotics for schizophrenia. Cochrane Database Syst Rev 2010(3):CD006654
   Google Scholar
• Osuntokun O, Millen B, Xu WI, et al. Metabolic parameters in patients treated with olanzapine or other atypical antipsychotics. J Psychopharmacol 2011;25(5):630-8
   PubMed Web of Science ®Google Scholar
• Cohen D, Bonnot O, Bodeau N, et al. Adverse effects of second-generation antipsychotics in children and adolescents: a Bayesian meta-analysis. J Clin Psychopharmacol 2012;32(3):309-16
   PubMed Web of Science ®Google Scholar
• Maayan L, Correll CU. Weight gain and metabolic risks associated with antipsychotic medications in children and adolescents. J Child Adolesc Psychopharmacol 2011;21(6):517-35
   PubMed Web of Science ®Google Scholar
• Citrome L. Quantifying risk: the role of absolute and relative measures in interpreting risk of adverse reactions from product labels of antipsychotic medications. Curr Drug Saf 2009;4(3):229-37
   PubMedGoogle Scholar
• Citrome L. Adjunctive aripiprazole, olanzapine, or quetiapine for major depressive disorder: an analysis of number needed to treat, number needed to harm, and likelihood to be helped or harmed. Postgrad Med 2010;122(4):39-48
   PubMed Web of Science ®Google Scholar
• Citrome L. Olanzapine-fluoxetine combination for the treatment of bipolar depression. Expert Opin Pharmacother 2011;12(17):2751-8
   PubMed Web of Science ®Google Scholar
• Kishi T, Kafantaris V, Sunday S, et al. Are antipsychotics effective for the treatment of anorexia nervosa? Results from a systematic review and meta-analysis. J Clin Psychiatry 2012;73(6):e757-66
   PubMedGoogle Scholar
• McKnight RF, Park RJ. Atypical antipsychotics and anorexia nervosa: a review. Eur Eat Disord Rev 2010;18(1):10-21
   PubMed Web of Science ®Google Scholar
• Lebow J, Sim LA, Erwin PJ, Murad MH. The effect of atypical antipsychotic medications in individuals with anorexia nervosa: a systematic review and meta-analysis. Int J Eat Disord 2013;46(4):332-9
   PubMed Web of Science ®Google Scholar
• Montgomery W, Treuer T, Karagianis J, et al. Orally disintegrating olanzapine review: effectiveness, patient preference, adherence, and other properties. Patient Prefer Adherence 2012;6:109-25
   PubMed Web of Science ®Google Scholar
• Kusumi I, Honda M, Uemura K, et al. Effect of olanzapine orally disintegrating tablet versus oral standard tablet on body weight in patients with schizophrenia: a randomized open-label trial. Prog Neuropsychopharmacol Biol Psychiatry 2012;36(2):313-17
   PubMed Web of Science ®Google Scholar
• Maher AR, Maglione M, Bagley S, et al. Efficacy and comparative effectiveness of atypical antipsychotic medications for off-label uses in adults: a systematic review and meta-analysis. JAMA 2011;306(12):1359-69
   PubMed Web of Science ®Google Scholar
• Stigler KA, Mullett JE, Erickson CA, et al. Paliperidone for irritability in adolescents and young adults with autistic disorder. Psychopharmacology (Berl) 2012;223(2):237-45
   PubMed Web of Science ®Google Scholar
• Asmal L, Flegar SJ, Wang J, et al. Quetiapine versus other atypical antipsychotics for schizophrenia. Cochrane Database Syst Rev 2013;11:CD006625
   PubMed Web of Science ®Google Scholar
• Suttajit S, Srisurapanont M, Xia J, et al. Quetiapine versus typical antipsychotic medications for schizophrenia. Cochrane Database Syst Rev 2013;5:CD007815
   PubMedGoogle Scholar
• Coe HV, Hong IS. Safety of low doses of quetiapine when used for insomnia. Ann Pharmacother 2012;46(5):718-22
   PubMed Web of Science ®Google Scholar
• Powers PS, Klabunde M, Kaye W. Double-blind placebo-controlled trial of quetiapine in anorexia nervosa. Eur Eat Disord Rev 2012;20(4):331-4
   PubMed Web of Science ®Google Scholar
• Komossa K, Rummel-Kluge C, Schwarz S, et al. Risperidone versus other atypical antipsychotics for schizophrenia. Cochrane Database Syst Rev 2011(1):CD006626
   Google Scholar
• Safer DJ. A comparison of risperidone-induced weight gain across the age span. J Clin Psychopharmacol 2004;24(4):429-36
   PubMed Web of Science ®Google Scholar
• Loy JH, Merry SN, Hetrick SE, Stasiak K. Atypical antipsychotics for disruptive behaviour disorders in children and youths. Cochrane Database Syst Rev 2012;9:CD008559
   PubMed Web of Science ®Google Scholar
• Covell NH, McEvoy JP, Schooler NR, et al. Effectiveness of switching from long-acting injectable fluphenazine or haloperidol decanoate to long-acting injectable risperidone microspheres: an open-label, randomized controlled trial. J Clin Psychiatry 2012;73(5):669-75
   PubMed Web of Science ®Google Scholar
• De Hert M, Mittoux A, He Y, Peuskens J. A head-to-head comparison of sertindole and risperidone on metabolic parameters. Schizophr Res 2010;123(2-3):276-7
   PubMed Web of Science ®Google Scholar
• Hale AS, Azorin JM, Lemming OM, Maehlum E. Sertindole in the long-term treatment of schizophrenia. Int Clin Psychopharmacol 2012;27(4):231-7
   PubMed Web of Science ®Google Scholar
• Komossa K, Rummel-Kluge C, Hunger H, et al. Ziprasidone versus other atypical antipsychotics for schizophrenia. Cochrane Database Syst Rev 2009(4):CD006627
   PubMed Web of Science ®Google Scholar
• Pappadopulos E, Newcomer JW, Kolluri S. Changes in weight, plasma lipids, and glucose in adults treated with ziprasidone: a comprehensive analysis of pfizer-initiated clinical trials. J Clin Psychiatry 2012;73(6):e742-8
   PubMedGoogle Scholar
• Karayal ON, Glue P, Bachinsky M, et al. Switching from quetiapine to ziprasidone: a sixteen-week, open-label, multicenter study evaluating the effectiveness and safety of ziprasidone in outpatient subjects with schizophrenia or schizoaffective disorder. J Psychiatr Pract 2011;17(2):100-9
   PubMed Web of Science ®Google Scholar
• Lee HB, Yoon BH, Kwon YJ, et al. The efficacy and safety of switching to ziprasidone from olanzapine in patients with bipolar I disorder: an 8-week, multicenter, open-label study. Clin Drug Investig 2013;33(10):743-53
   PubMed Web of Science ®Google Scholar
• Kim SW, Shin IS, Kim JM, et al. Effectiveness of switching from aripiprazole to ziprasidone in patients with schizophrenia. Clin Neuropharmacol 2010;33(3):121-5
   PubMed Web of Science ®Google Scholar
• Gao KM, Pappadopulos E, Karayal ON, et al. Risk for adverse events and discontinuation due to adverse events of ziprasidone monotherapy relative to placebo in the acute treatment of bipolar depression, mania, and schizophrenia. J Clin Psychopharmacol 2013;33(3):425-31
   PubMed Web of Science ®Google Scholar
• Dent R, Blackmore A, Peterson J, et al. Changes in body weight and psychotropic drugs: a systematic synthesis of the literature. PLoS One 2012;7:6
   Web of Science ®Google Scholar
• Mitchell AJ, Delaffon V, Vancampfort D, et al. Guideline concordant monitoring of metabolic risk in people treated with antipsychotic medication: systematic review and meta-analysis of screening practices. Psychol Med 2012;42(1):125-47
   PubMed Web of Science ®Google Scholar
• Koch DA, Scott AJ. Weight gain and lipid-glucose profiles among patients taking antipsychotic medications: comparisons for prescriptions administered using algorithms versus usual care. J Psychiatr Ment Health Nurs 2012;19(5):389-94
   PubMed Web of Science ®Google Scholar
• Ho J, Panagiotopoulos C, McCrindle B, et al. Management recommendations for metabolic complications associated with second-generation antipsychotic use in children and youth. Paediatr Child Health 2011;16(9):575-80
   PubMed Web of Science ®Google Scholar
• Calarge CA, Xie D, Fiedorowicz JG, et al. Rate of weight gain and cardiometabolic abnormalities in children and adolescents. J Pediatr 2012;161(6):1010-15
   PubMed Web of Science ®Google Scholar
• Eapen V, Shiers D, Curtis J. Bridging the gap from evidence to policy and practice: reducing the progression to metabolic syndrome for children and adolescents on antipsychotic medication. Aust N Z J Psychiatry 2013;47(5):435-42
   PubMed Web of Science ®Google Scholar
• Millen BA, Campbell GM, Beasley CM. Weight changes over time in adults treated with the oral or depot formulations of olanzapine: a pooled analysis of 86 clinical trials. J Psychopharmacol 2011;25(5):639-45
   PubMed Web of Science ®Google Scholar
• Hoffmann VP, Case M, Stauffer VL, et al. Predictive value of early changes in triglycerides and weight for longer-term changes in metabolic measures during olanzapine, ziprasidone or aripiprazole treatment for schizophrenia and schizoaffective disorder post hoc analyses of 3 randomized, controlled clinical trials. J Clin Psychopharmacol 2010;30(6):656-60
   PubMed Web of Science ®Google Scholar
• Mukundan A, Faulkner G, Cohn T, Remington G. Antipsychotic switching for people with schizophrenia who have neuroleptic-induced weight or metabolic problems. Cochrane Database Syst Rev 2010(12):CD006629
   Google Scholar
• Cerovecki A, Musil R, Klimke A, et al. Withdrawal symptoms and rebound syndromes associated with switching and discontinuing atypical antipsychotics: theoretical background and practical recommendations. CNS Drugs 2013;27(7):545-72
   PubMed Web of Science ®Google Scholar
• Stroup TS, Byerly MJ, Nasrallah HA, et al. Effects of switching from olanzapine, quetiapine, and risperidone to aripiprazole on 10-year coronary heart disease risk and metabolic syndrome status: results from a randomized controlled trial. Schizophr Res 2013;146(1-3):190-5
   PubMed Web of Science ®Google Scholar
• Schulz C, Haight RJ. Safety of olanzapine use in adolescents. Expert Opin Drug Saf 2013;12(5):777-82
   PubMed Web of Science ®Google Scholar
• Warnez S, Alessi-Severini S. Clozapine: a review of clinical practice guidelines and prescribing trends. BMC Psychiatry 2014;14(1):102
   PubMedGoogle Scholar
• Soares-Weiser K, Bechard-Evans L, Lawson AH, et al. Time to all-cause treatment discontinuation of olanzapine compared to other antipsychotics in the treatment of schizophrenia: a systematic review and meta-analysis. Eur Neuropsychopharmacol 2013;23(2):118-25
   PubMed Web of Science ®Google Scholar
• Newall H, Myles N, Ward PB, et al. Efficacy of metformin for prevention of weight gain in psychiatric populations: a review. Int Clin Psychopharmacol 2012;27(2):69-75
   PubMed Web of Science ®Google Scholar
• Fiedorowicz JG, Miller DD, Bishop JR, et al. Systematic Review and Meta-analysis of Pharmacological Interventions for Weight Gain from Antipsychotics and Mood Stabilizers. Curr Psychiatry Rev 2012;8(1):25-36
   PubMedGoogle Scholar
• Curtis J, Newall H, Myles N, et al. Considering metformin in cardiometabolic protection in psychosis. Acta Psychiatr Scand 2012;126(4):302-3
   PubMed Web of Science ®Google Scholar
• Caemmerer J, Correll CU, Maayan L. Acute and maintenance effects of non-pharmacologic interventions for antipsychotic associated weight gain and metabolic abnormalities: a meta-analytic comparison of randomized controlled trials. Schizophr Res 2012;140(1-3):159-68
   PubMed Web of Science ®Google Scholar
• Zhang JP, Weiss JJ, McCardle M, et al. Effectiveness of a cognitive behavioral weight management intervention in obese patients with psychotic disorders compared to patients with nonpsychotic disorders or no psychiatric disorders results from a 12-month, real-world study. J Clin Psychopharmacol 2012;32(4):458-64
   PubMed Web of Science ®Google Scholar
• McCloughen A, Foster K. Weight gain associated with taking psychotropic medication: an integrative review. Int J Ment Health Nurs 2011;20(3):202-22
   PubMed Web of Science ®Google Scholar
• Maayan L, Vakhrusheva J, Correll CU. Effectiveness of medications used to attenuate antipsychotic-related weight gain and metabolic abnormalities: a systematic review and meta-analysis. Neuropsychopharmacology 2010;35(7):1520-30
   PubMed Web of Science ®Google Scholar
• Daumit GL, Dickerson FB, Wang NY, et al. A behavioral weight-loss intervention in persons with serious mental illness. N Engl J Med 2013;368(17):1594-602
   PubMed Web of Science ®Google Scholar
• Reynolds GP, Yevtushenko OO, Gordon S, et al. The obesity risk gene FTO influences body mass in chronic schizophrenia but not initial antipsychotic drug-induced weight gain in first-episode patients. Int J Neuropsychopharmacol 2013;16(6):1421-5
   PubMed Web of Science ®Google Scholar
• Moteshafi H, Zhornitsky S, Brunelle S, Stip E. Comparing tolerability of olanzapine in schizophrenia and affective disorders: a meta-analysis. Drug Saf 2012;35(10):819-36
   PubMed Web of Science ®Google Scholar
• Schwarz E, Steiner J, Guest PC, et al. Investigation of molecular serum profiles associated with predisposition to antipsychotic-induced weight gain. World J Biol Psychiatry 2013; [Epub ahead of print]
   PubMed Web of Science ®Google Scholar
• Schuster JP, Raucher-Chene D, Lemogne C, et al. Impact of switching or initiating antipsychotic treatment on body weight during a 6-month follow-up in a cohort of patients with schizophrenia. J Clin Psychopharmacol 2012;32(5):672-7
   PubMed Web of Science ®Google Scholar
• McIntyre RS, Cha DS, Kim RD, Mansur RB. A review of FDA-approved treatment options in bipolar depression. CNS Spectr 2013;18:1-21
   PubMed Web of Science ®Google Scholar
• Hermes E, Nasrallah H, Davis V, et al. The association between weight change and symptom reduction in the CATIE schizophrenia trial. Schizophr Res 2011;128(1-3):166-70
   PubMed Web of Science ®Google Scholar
• Kane JM, Mackle M, Snow-Adami L, et al. A randomized placebo-controlled trial of asenapine for the prevention of relapse of schizophrenia after long-term treatment. J Clin Psychiatry 2011;72(3):349-55
   PubMed Web of Science ®Google Scholar
• Kane JM, Cohen M, Zhao J, et al. Efficacy and safety of asenapine in a placebo- and haloperidol-controlled trial in patients with acute exacerbation of schizophrenia. J Clin Psychopharmacol 2010;30(2):106-15
   PubMed Web of Science ®Google Scholar
• McIntyre RS, Cohen M, Zhao J, et al. Asenapine in the treatment of acute mania in bipolar I disorder: a randomized, double-blind, placebo-controlled trial. J Affect Disord 2010;122(1-2):27-38
   PubMed Web of Science ®Google Scholar
• Vieta E, Ramey T, Keller D, et al. Ziprasidone in the treatment of acute mania: a 12-week, placebo-controlled, haloperidol-referenced study. J Psychopharmacol 2010;24(4):547-58
   PubMed Web of Science ®Google Scholar
• Loebel A, Cucchiaro J, Silva R, et al. Lurasidone monotherapy in the treatment of bipolar I depression: a randomized, double-blind, placebo-controlled study. Am J Psychiatry 2014;171(2):160-8
   PubMed Web of Science ®Google Scholar
• Loebel A, Cucchiaro J, Sarma K, et al. Efficacy and safety of lurasidone 80 mg/day and 160 mg/day in the treatment of schizophrenia: a randomized, double-blind, placebo- and active-controlled trial. Schizophr Res 2013;145(1-3):101-9
   PubMed Web of Science ®Google Scholar
• Nasrallah HA, Silva R, Phillips D, et al. Lurasidone for the treatment of acutely psychotic patients with schizophrenia: a 6-week, randomized, placebo-controlled study. J Psychiatr Res 2013;47(5):670-7
   PubMed Web of Science ®Google Scholar
• Meltzer HY, Cucchiaro J, Silva R, et al. Lurasidone in the treatment of schizophrenia: a randomized, double-blind, placebo- and olanzapine-controlled study. Am J Psychiatry 2011;168(9):957-67
   PubMed Web of Science ®Google Scholar
• Berwaerts J, Melkote R, Nuamah I, Lim P. A randomized, placebo- and active-controlled study of paliperidone extended-release as maintenance treatment in patients with bipolar I disorder after an acute manic or mixed episode. J Affect Disord 2012;138(3):247-58
   PubMed Web of Science ®Google Scholar
• Katagiri H, Takita Y, Tohen M, et al. Efficacy and safety of olanzapine in the treatment of Japanese patients with bipolar I disorder in a current manic or mixed episode: a randomized, double-blind, placebo- and haloperidol-controlled study. J Affect Disord 2012;136(3):476-84
   PubMed Web of Science ®Google Scholar
• Tohen M, McDonnell DP, Case M, et al. Randomised, double-blind, placebo-controlled study of olanzapine in patients with bipolar I depression. Br J Psychiatry 2012;201(5):376-82
   PubMed Web of Science ®Google Scholar
• Vieta E, Montgomery S, Sulaiman AH, et al. A randomized, double-blind, placebo-controlled trial to assess prevention of mood episodes with risperidone long-acting injectable in patients with bipolar I disorder. Eur Neuropsychopharmacol 2012;22(11):825-35
   PubMed Web of Science ®Google Scholar
• Katagiri H, Tohen M, McDonnell DP, et al. Efficacy and safety of olanzapine for treatment of patients with bipolar depression: japanese subpopulation analysis of a randomized, double-blind, placebo-controlled study. BMC Psychiatry 2013;13:138
   PubMed Web of Science ®Google Scholar
• Zanarini MC, Schulz SC, Detke HC, et al. A dose comparison of olanzapine for the treatment of borderline personality disorder: a 12-week randomized, double-blind, placebo-controlled study. J Clin Psychiatry 2011;72(10):1353-62
   PubMed Web of Science ®Google Scholar
• Berwaerts J, Xu H, Nuamah I, et al. Evaluation of the efficacy and safety of paliperidone extended-release in the treatment of acute mania: a randomized, double-blind, dose-response study. J Affect Disord 2012;136(1-2):e51-60
   PubMed Web of Science ®Google Scholar
• Canuso CM, Lindenmayer JP, Kosik-Gonzalez C, et al. A randomized, double-blind, placebo-controlled study of 2 dose ranges of paliperidone extended-release in the treatment of subjects with schizoaffective disorder. J Clin Psychiatry 2010;71(5):587-98
   PubMed Web of Science ®Google Scholar
• Canuso CM, Schooler N, Carothers J, et al. Paliperidone extended-release in schizoaffective disorder: a randomized, controlled study comparing a flexible dose with placebo in patients treated with and without antidepressants and/or mood stabilizers. J Clin Psychopharmacol 2010;30(5):487-95
   PubMed Web of Science ®Google Scholar
• Singh J, Robb A, Vijapurkar U, et al. A randomized, double-blind study of paliperidone extended-release in treatment of acute schizophrenia in adolescents. Biol Psychiatry 2011;70(12):1179-87
   PubMed Web of Science ®Google Scholar
• Hough D, Gopal S, Vijapurkar U, et al. Paliperidone palmitate maintenance treatment in delaying the time-to-relapse in patients with schizophrenia: a randomized, double-blind, placebo-controlled study. Schizophr Res 2010;116(2-3):107-17
   PubMed Web of Science ®Google Scholar
• Kramer M, Litman R, Hough D, et al. Paliperidone palmitate, a potential long-acting treatment for patients with schizophrenia. Results of a randomized, double-blind, placebo-controlled efficacy and safety study. Int J Neuropsychopharmacol 2010;13(5):635-47
   PubMed Web of Science ®Google Scholar
• Pandina GJ, Lindenmayer JP, Lull J, et al. A randomized, placebo-controlled study to assess the efficacy and safety of 3 doses of paliperidone palmitate in adults with acutely exacerbated schizophrenia. J Clin Psychopharmacol 2010;30(3):235-44
   PubMed Web of Science ®Google Scholar
• Takahashi N, Takahashi M, Saito T, et al. Randomized, placebo-controlled, double-blind study assessing the efficacy and safety of paliperidone palmitate in Asian patients with schizophrenia. Neuropsychiatr Dis Treat 2013;8:1889-98
   PubMed Web of Science ®Google Scholar
• Gopal S, Hough DW, Xu H, et al. Efficacy and safety of paliperidone palmitate in adult patients with acutely symptomatic schizophrenia: a randomized, double-blind, placebo-controlled, dose-response study. Int Clin Psychopharmacol 2010;25(5):247-56
   PubMed Web of Science ®Google Scholar
• Findling RL, McKenna K, Earley WR, et al. Efficacy and safety of quetiapine in adolescents with schizophrenia investigated in a 6-week, double-blind, placebo-controlled trial. J Child Adolesc Psychopharmacol 2012;22(5):327-42
   PubMed Web of Science ®Google Scholar
• McElroy SL, Weisler RH, Chang W, et al. A double-blind, placebo-controlled study of quetiapine and paroxetine as monotherapy in adults with bipolar depression (EMBOLDEN II). J Clin Psychiatry 2010;71(2):163-74
   PubMed Web of Science ®Google Scholar
• Pathak S, Findling RL, Earley WR, et al. Efficacy and safety of quetiapine in children and adolescents with mania associated with bipolar I disorder: a 3-week, double-blind, placebo-controlled trial. J Clin Psychiatry 2013;74(1):e100-9
   PubMed Web of Science ®Google Scholar
• Weisler RH, Nolen WA, Neijber A, Trial 144 Study Investigators. Continuation of quetiapine versus switching to placebo or lithium for maintenance treatment of bipolar I disorder (Trial 144: a randomized controlled study). J Clin Psychiatry 2011;72(11):1452-64
   PubMed Web of Science ®Google Scholar
• Young AH, McElroy SL, Bauer M, et al. A double-blind, placebo-controlled study of quetiapine and lithium monotherapy in adults in the acute phase of bipolar depression (EMBOLDEN I). J Clin Psychiatry 2010;71(2):150-62
   PubMed Web of Science ®Google Scholar
• Katila H, Mezhebovsky I, Mulroy A, et al. Randomized, double-blind study of the efficacy and tolerability of extended release quetiapine fumarate (quetiapine XR) monotherapy in elderly patients with major depressive disorder. Am J Geriatr Psychiatry 2013;21(8):769-84
   PubMed Web of Science ®Google Scholar
• Katzman MA, Brawman-Mintzer O, Reyes EB, et al. Extended release quetiapine fumarate (quetiapine XR) monotherapy as maintenance treatment for generalized anxiety disorder: a long-term, randomized, placebo-controlled trial. Int Clin Psychopharmacol 2011;26(1):11-24
   PubMed Web of Science ®Google Scholar
• Bandelow B, Chouinard G, Bobes J, et al. Extended-release quetiapine fumarate (quetiapine XR): a once-daily monotherapy effective in generalized anxiety disorder. Data from a randomized, double-blind, placebo- and active-controlled study. Int J Neuropsychopharmacol 2010;13(3):305-20
   PubMed Web of Science ®Google Scholar
• Bortnick B, El-Khalili N, Banov M, et al. Efficacy and tolerability of extended release quetiapine fumarate (quetiapine XR) monotherapy in major depressive disorder: a placebo-controlled, randomized study. J Affect Disord 2011;128(1-2):83-94
   PubMed Web of Science ®Google Scholar
• Cutler AJ, Datto C, Nordenhem A, et al. Extended-release quetiapine as monotherapy for the treatment of adults with acute mania: a randomized, double-blind, 3-week trial. Clin Ther 2011;33(11):1643-58
   PubMed Web of Science ®Google Scholar
• Khan A, Joyce M, Atkinson S, et al. A randomized, double-blind study of once-daily extended release quetiapine fumarate (quetiapine XR) monotherapy in patients with generalized anxiety disorder. J Clin Psychopharmacol 2011;31(4):418-28
   PubMed Web of Science ®Google Scholar
• Liebowitz M, Lam RW, Lepola U, et al. Efficacy and tolerability of extended release quetiapine fumarate monotherapy as maintenance treatment of major depressive disorder: a randomized, placebo-controlled trial. Depress Anxiety 2010;27(10):964-76
   PubMed Web of Science ®Google Scholar
• Mezhebovsky I, Magi K, She F, et al. Double-blind, randomized study of extended release quetiapine fumarate (quetiapine XR) monotherapy in older patients with generalized anxiety disorder. Int J Geriatr Psychiatry 2013;28(6):615-25
   PubMed Web of Science ®Google Scholar
• Suppes T, Datto C, Minkwitz M, et al. Effectiveness of the extended release formulation of quetiapine as monotherapy for the treatment of acute bipolar depression. J Affect Disord 2010;121(1-2):106-15
   PubMed Web of Science ®Google Scholar
• Wang G, McIntyre A, Earley WR, et al. A randomized, double-blind study of the efficacy and tolerability of extended-release quetiapine fumarate (quetiapine XR) monotherapy in patients with major depressive disorder. Neuropsychiatr Dis Treat 2014;10:201-16
   PubMed Web of Science ®Google Scholar
• Quiroz JA, Yatham LN, Palumbo JM, et al. Risperidone long-acting injectable monotherapy in the maintenance treatment of bipolar I disorder. Biol Psychiatry 2010;68(2):156-62
   PubMed Web of Science ®Google Scholar
• Fleischhacker WW, McQuade RD, Marcus RN, et al. A double-blind, randomized comparative study of aripiprazole and olanzapine in patients with schizophrenia. Biol Psychiatry 2009;65(6):510-17
   PubMed Web of Science ®Google Scholar
• Buchanan RW, Panagides J, Zhao J, et al. Asenapine versus olanzapine in people with persistent negative symptoms of schizophrenia. J Clin Psychopharmacol 2012;32(1):36-45
   PubMed Web of Science ®Google Scholar
• Bobo WV, Jayathilake K, Lee MA, Meltzer HY. Changes in weight and body mass index during treatment with melperone, clozapine and typical neuroleptics. Psychiatry Res 2010;176(2-3):114-19
   PubMed Web of Science ®Google Scholar
• Potkin SG, Ogasa M, Cucchiaro J, Loebel A. Double-blind comparison of the safety and efficacy of lurasidone and ziprasidone in clinically stable outpatients with schizophrenia or schizoaffective disorder. Schizophr Res 2011;132(2-3):101-7
   PubMed Web of Science ®Google Scholar
• McEvoy JP, Citrome L, Hernandez D, et al. Effectiveness of lurasidone in patients with schizophrenia or schizoaffective disorder switched from other antipsychotics: a randomized, 6-week, open-label study. J Clin Psychiatry 2013;74(2):170-9
   PubMed Web of Science ®Google Scholar
• Shah S, Joshi D. Tolerability and efficacy of paliperidone ER compared to olanzapine in the treatment of schizophrenia: a randomized, double-blind, multicentric trial. Ind Psychiatry J 2011;20(1):25-31
   PubMedGoogle Scholar
• Ou JJ, Xu Y, Chen HH, et al. Comparison of metabolic effects of ziprasidone versus olanzapine treatment in patients with first-episode schizophrenia. Psychopharmacology (Berl) 2013;225(3):627-35
   PubMed Web of Science ®Google Scholar
• Kwon JS, Mittoux A, Hwang JY, et al. The efficacy and safety of 12 weeks of treatment with sertindole or olanzapine in patients with chronic schizophrenia who did not respond successfully to their previous treatments: a randomized, double-blind, parallel-group, flexible-dose study. Int Clin Psychopharmacol 2012;27(6):326-35
   PubMed Web of Science ®Google Scholar
• McDonnell DP, Kryzhanovskaya LA, Zhao F, et al. Comparison of metabolic changes in patients with schizophrenia during randomized treatment with intramuscular olanzapine long-acting injection versus oral olanzapine. Hum Psychopharmacol 2011;26(6):422-33
   PubMed Web of Science ®Google Scholar
• Bushe C, Sniadecki J, Bradley AJ, Poole Hoffmann V. Comparison of metabolic and prolactin variables from a six-month randomised trial of olanzapine and quetiapine in schizophrenia. J Psychopharmacol 2010;24(7):1001-9
   PubMed Web of Science ®Google Scholar
• Schreiner A, Niehaus D, Shuriquie NA, et al. Metabolic effects of paliperidone extended release versus oral olanzapine in patients with schizophrenia: a prospective, randomized, controlled trial. J Clin Psychopharmacol 2012;32(4):449-57
   PubMed Web of Science ®Google Scholar
• Hill AL, Sun B, Karagianis JL, et al. Dose-associated changes in safety and efficacy parameters observed in a 24-week maintenance trial of olanzapine long-acting injection in patients with schizophrenia. BMC Psychiatry 2011;11
   PubMed Web of Science ®Google Scholar
• Kane JM, Detke HC, Naber D, et al. Olanzapine long-acting injection: a 24-week, randomized, double-blind trial of maintenance treatment in patients with schizophrenia. Am J Psychiatry 2010;167(2):181-9
   PubMed Web of Science ®Google Scholar
• Mitchell M, Kothare P, Bergstrom R, et al. Single- and multiple-dose pharmacokinetic, safety, and tolerability profiles of olanzapine long-acting injection: an open-label, multicenter, nonrandomized study in patients with schizophrenia. Clin Ther 2013;35(12):1890-908
   PubMed Web of Science ®Google Scholar
• Schmauss M, Jukic V, Siracusano A, et al. Flexible dosing with paliperidone ER in the treatment of patients with acutely exacerbated schizophrenia: results from a single-arm, open-label study. Curr Med Res Opin 2012;28(8):1395-404
   PubMed Web of Science ®Google Scholar
• Kim SW, Yoon JS, Kim YS, et al. The effect of paliperidone extended release on subjective well-being and responses in patients with schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 2012;38(2):228-35
   PubMed Web of Science ®Google Scholar
• Canuso CM, Bossie CA, Amatniek J, et al. Paliperidone extended-release tablets in patients with recently diagnosed schizophrenia. Early Interv Psychiatry 2010;4(1):64-78
   PubMed Web of Science ®Google Scholar
• Nasrallah HA, Gopal S, Gassmann-Mayer C, et al. A controlled, evidence-based trial of paliperidone palmitate, a long-acting injectable antipsychotic, in schizophrenia. Neuropsychopharmacology 2010;35(10):2072-82
   PubMed Web of Science ®Google Scholar
• Pandina G, Lane R, Gopal S, et al. A double-blind study of paliperidone palmitate and risperidone long-acting injectable in adults with schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 2011;35(1):218-26
   PubMed Web of Science ®Google Scholar
• Li H, Rui Q, Ning X, et al. A comparative study of paliperidone palmitate and risperidone long-acting injectable therapy in schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 2011;35(4):1002-8
   PubMed Web of Science ®Google Scholar
• Honer WG, MacEwan GW, Gendron A, et al. A randomized, double-blind, placebo-controlled study of the safety and tolerability of high-dose quetiapine in patients with persistent symptoms of schizophrenia or schizoaffective disorder. J Clin Psychiatry 2012;73(1):13-20
   PubMed Web of Science ®Google Scholar
• Loebel A, Cucchiaro J, Xu J, et al. Effectiveness of lurasidone vs. quetiapine XR for relapse prevention in schizophrenia: a 12-month, double-blind, noninferiority study. Schizophr Res 2013;147(1):95-102
   PubMed Web of Science ®Google Scholar
• Zhang H, Li H, Shu L, et al. Double-blind comparison of ziprasidone and risperidone in the treatment of Chinese patients with acute exacerbation of schizophrenia. Neuropsychiatr Dis Treat 2011;7:77-85
   PubMed Web of Science ®Google Scholar
• Kane JM, Potkin SG, Daniel DG, Buckley PF. A double-blind, randomized study comparing the efficacy and safety of sertindole and risperidone in patients with treatment-resistant schizophrenia. J Clin Psychiatry 2011;72(2):194-204
   PubMed Web of Science ®Google Scholar
• Meltzer HY, Lindenmayer JP, Kwentus J, et al. A six month randomized controlled trial of long acting injectable risperidone 50 and 100mg in treatment resistant schizophrenia. Schizophr Res 2014;154(1-3):14-22
   PubMed Web of Science ®Google Scholar
• Parellada E, Kouniakis F, Siurkute A, et al. Safety and efficacy of long-acting injectable risperidone in daily practice: an open-label, noninterventional, prospective study in schizophrenia and related disorders. Int Clin Psychopharmacol 2010;25(3):149-54
   PubMed Web of Science ®Google Scholar